Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investment by major pharmaceutical companies in antimicrobial research and development. Although smaller companies are stepping forward to address this gap, th...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 42; no. 5; pp. 657 - 668
Main Authors Talbot, George H., Bradley, John, Edwards, John E., Gilbert, David, Scheld, Michael, Bartlett, John G.
Format Journal Article
LanguageEnglish
Published Chicago, IL The University of Chicago Press 01.03.2006
University of Chicago Press
Oxford University Press
Subjects
Acinetobacter
Anti-Bacterial Agents
Antibacterials
Antibiotics
Antimicrobials
Bacteria
Biological and medical sciences
Business structures
Communicable Diseases, Emerging - drug therapy
Drug Approval
Drugs
Drugs, Investigational
Humans
Infections
Infectious diseases
Medical sciences
Pathogens
Patients
Pharmaceutical industry
Pipelines
Public Health
R&D
Research & development
Staphylococcus aureus
Task forces
Viewpoint
America
Infection
Antimicrobial agent
Online AccessGet full text

Cover

More Information
Summary:The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investment by major pharmaceutical companies in antimicrobial research and development. Although smaller companies are stepping forward to address this gap, their success is uncertain. The IDSA proposed legislative and other federal solutions to this emerging public health problem in its July 2004 policy report "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews." At this time, the legislative response cannot be predicted. To emphasize further the urgency of the problem for the benefit of legislators and policy makers and to capture the ongoing frustration our clinician colleagues experience in their frequent return to an inadequate medicine cabinet, the AATF has prepared this review to highlight pathogens that are frequently resistant to licensed antimicrobials and for which few, if any, potentially effective drugs are identifiable in the late-stage development pipeline.
Bibliography:istex:F4EDB8BC6DD20C10B176C38B5C98B7A2D9E16A22
ark:/67375/HXZ-TZFQ563F-4
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1058-4838
1537-6591
DOI:10.1086/499819